2008 Research
2007
Research
2006
Research
2005
Research
2004-2001 Research Archives
Sep 2005
Page Twenty Seven
Most chronic hepatitis C sufferers will develop cirrhosis in later life
Sep 02 2005
Can treating HCV prevent progression to cirrhosis?
Sep 01 2005
Issues in Cirrhosis
and Liver Transplantation
Aug 29 2005
Peginterferon
Alfa-2b Plus Ribavirin Elicits Sustained Response in Decompensated HCV
Patients
Accelerating regimen of
interferon plus ribavirin reduces post-transplantation HCV relapse
Aug 10 2005
Issues in Cirrhosis
Noninvasive predictive
model for HCV cirrhosis has high specificity and sensitivity
July 28 2005
Milk Thistle: Effects on
Liver Disease and Cirrhosis and Clinical Adverse Effects
Page Twenty Six
Care of the
Cirrhotic Patient
6/7/05
Combination Therapy of Low
Dose Ribavirin and Pegylated Interferon for Patients with HCV and End-Stage
Renal Disease on Dialysis
June 09 2005
Cognitive Function in HCV Patients with Advanced
Fibrosis Enrolled in the HALT-C Trial
June 09 2005
Starting treatment earlier and staying on treatment
longer may increase
treatment response rates
for certain hepatitis C patients
June 06 2005
Chronic liver disease and
consumption of raw oysters: a potentially lethal
combination--a review of Vibrio vulnificus septicemia.
The HALT-C Trial Group
reported their results treating patients with cirrhosis or bridging fibrosis
The Clinical Characteristics, Management and Outcomes
Of Patients 65 and Over With Chronic Hepatitis C in An Integrated Health
Care System.
Page Twenty Five
Safety and Efficacy Of Antiviral Therapy in Patients
With Decompensated Cirrhosis Associated With Chronic Hepatitis C Infection
May 18 2005
Treatment of
Cirrhotic HCV Patients with a Low Ascending Daily Dosing Regimen of
Consensus Interferon and Ribavirin
May 18 2005
Association Between
Liver Histology, Viral Kinetics and Outcome of Therapy with Peginterferon
Alfa-2a (Pegasys) Combination Therapy with Ribavirin
Previous studies have
shown that the presence of liver cirrhosis is associated with lower
sustained viral response (SVR) rates after peginterferon-ribavirin therapy.
May 05 2005
Pegylated Interferon
Maintenance Therapy Positively Impacts on Portal Hypertension Secondary to
HCV-related Cirrhosis
May 05 2005
Treatment of HCV in
Cirrhotic Patients
May 05 2005
Trial of
acarbose in hepatic encephalopathy
Mar 03 2005
Coagulation tests unlikely to reflect thrombin
generation in cirrhosis
Feb 28 2005
Malnutrition and Liver Cirrhosis: Scoping Out the
Signs
Short-Term Celebrex Safe Against Cirrhosis
Feb 28 2005
Page Twenty Four
Dispelling myths in
the treatment of hepatic encephalopathy
Jan 30 05
Page Twenty Three
Caffeine reduces risk
of elevated alanine aminotransferase
Jan 07 2005
Cardiac alterations in
cirrhosis: reversible after liver transplant
Jan 07 2005 |
